Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden-Reference-Cited by-同舟云学术

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Published:2018-05-09 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Morrison Carl^ORCID,Pabla Sarabjot,Conroy Jeffrey M.,Nesline Mary K.,Glenn Sean T.,Dressman Devin,Papanicolau-Sengos Antonios,Burgher Blake,Andreas Jonathan,Giamo Vincent,Qin Moachun,Wang Yirong,Lenzo Felicia L.,Omilian Angela,Bshara Wiam,Zibelman Matthew,Ghatalia Pooja,Dragnev Konstantin,Shirai Keisuke,Madden Katherine G.,Tafe Laura J.,Shah Neel,Kasuganti Deepa,de la Cruz-Merino Luis,Araujo Isabel,Saenger Yvonne,Bogardus Margaret,Villalona-Calero Miguel,Diaz Zuanel,Day Roger,Eisenberg Marcia,Anderson Steven M.,Puzanov Igor,Galluzzi Lorenzo,Gardner Mark,Ernstoff Marc S.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0344-8.pdf

Reference28 articles.

1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. https://doi.org/10.1056/NEJMoa1003466 .

2. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. https://doi.org/10.1056/NEJMoa1104621 .

3. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99. https://doi.org/10.1056/NEJMoa1406498 .

4. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013;369:122–33. https://doi.org/10.1056/NEJMoa1302369 .

5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521–32. https://doi.org/10.1056/NEJMoa1503093 .

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Analysis of the Prognostic Factors and Adverse Events in the Treatment of Mucosal Melanoma in a Single Centre;Journal of Clinical Medicine;2024-08-13

2. Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals;Journal of Drug Targeting;2024-08-07

3. Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis;International Journal of Dermatology;2024-08-04

4. Populations of triple negative and hormone receptor positive HER2 negative breast tumors share immune gene profiles;2024-08-02

5. Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition;International Journal of Cancer;2024-07-20